The San Diego-based startup uses a delivery technology platform that efficiently delivers nucleic acid drugs to various tissues in the body, including neurons, endothelial, and T cells, addressing issues that limited previous-generation platforms, such as poor pharmacokinetics and insufficient cellular uptake. This enables healthcare providers to deliver oligos in vivo at therapeutically relevant doses, making RNA medicines the modality of choice for personalized treatment.